Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Overview
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Companies Involved in Therapeutics Development
Caldan Therapeutics Ltd
Eli Lilly and Co
Fujian Haixi New Medicine Creation Co Ltd
Halo Therapeutics Ltd
Hyundai Pharma Co Ltd
Ildong Pharmaceutical Co Ltd
Johnson & Johnson
Merck & Co Inc
Scohia Pharma Inc
Takeda Pharmaceutical Co Ltd
TiumBio Co Ltd
Zydus Lifesciences Ltd
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Drug Profiles
fasiglifam - Drug Profile
Product Description
Mechanism Of Action
History of Events
HLTX-3 - Drug Profile
Product Description
Mechanism Of Action
HOB-047 - Drug Profile
Product Description
Mechanism Of Action
HXP-0057 - Drug Profile
Product Description
Mechanism Of Action
History of Events
IDG-16177 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LY-2922470 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MK-2305 - Drug Profile
Product Description
Mechanism Of Action
NCE-406 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SCO-267 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Agonize FFAR1 and PPARG for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Agonize GPR40 for Type 2 Diabetes Mellitus - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Agonize GPR40 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Agonize PPAR Gamma and GPR40 for Diabetes - Drug Profile
Product Description
Mechanism Of Action
TUG-770 - Drug Profile
Product Description
Mechanism Of Action
ZYDG-2 - Drug Profile
Product Description
Mechanism Of Action
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Dormant Products
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Discontinued Products
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Product Development Milestones
Featured News & Press Releases
Jun 30, 2021: Ildong Pharmaceutical starts phase 1 study of new diabetes therapy in Germany
Jun 28, 2021: The clinical results of SCO-267 was presented at the Virtual 81st Scientific Sessions - American Diabetes Association: First report on the clinical data of a GPR40 full agonist in the phase 1 trial
Apr 21, 2021: Ildong Pharmaceutical applied for clinical plan approval for new diabetes drug in Europe
Feb 08, 2021: Publication of a preclinical study: chronic exposure to SCO-267, a GPR40, is effective in treating diabetes in preclinical models
Sep 15, 2020: Conference presentation on medicil chemistry research of GPR40 full agonist (SCO-267)
Sep 10, 2020: GPR40 full agonist (SCO-267) medicil chemistry research
Jul 28, 2020: Publication regarding a preclinical study; SCO-267, a GPR40 full agonist, is a novel strategy to treat FLD
May 10, 2020: Hyundai Pharm’s diabetes drug gets FDA approval for phase 2 clinical trial
Dec 09, 2019: SCOHIA initiates a Phase 1 study of a GPR40 full agonist (SCO-267)
Jun 17, 2019: Presentation of new preclinical data of SCO-267, a GPR40 agonist, at The American Diabetes Association’s 79th Scientific Sessions
Jun 11, 2019: Publication regarding a preclinical study of SCO-267, a novel GPR40 agonist
Jun 05, 2019: SCOHIA PHARMA to present new preclinical data of SCO267, a GPR40 agonist, at The American Diabetes Association’s 79th Scientific Sessions
Dec 26, 2013: Takeda Announces Termition of Fasiglifam Development
Sep 26, 2013: Takeda Presents Fasiglifam Phase III data at the 49th Annual Meeting of the European Association for the Study of Diabetes
May 16, 2013: Takeda Pharma Announces Presentation Of Phase III Clinical Trial Results Of Fasiglifam At 56th Annual Meeting Of Japan Diabetes Society
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Caldan Therapeutics Ltd, 2022
Pipeline by Eli Lilly and Co, 2022
Pipeline by Fujian Haixi New Medicine Creation Co Ltd, 2022
Pipeline by Halo Therapeutics Ltd, 2022
Pipeline by Hyundai Pharma Co Ltd, 2022
Pipeline by Ildong Pharmaceutical Co Ltd, 2022
Pipeline by Johnson & Johnson, 2022
Pipeline by Merck & Co Inc, 2022
Pipeline by Scohia Pharma Inc, 2022
Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Pipeline by TiumBio Co Ltd, 2022
Pipeline by Zydus Lifesciences Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022